S&P Futures
3,990.25 +7.25 (+0.18%) Dow Futures
32,514.00 +58.00 (+0.18%) Nasdaq Futures
12,701.50 +13.00 (+0.10%) Russell 2000 Futures
1,768.30 +7.60 (+0.43%) Crude Oil
66.83 -0.81 (-1.20%) Gold
1,985.80 +3.00 (+0.15%)
X4 Pharmaceuticals, Inc. (48Q.F)
Chart Events
Performance Outlook
| Previous Close | 0.8450 |
| Open | 0.8000 |
| Bid | 0.8050 x N/A |
| Ask | 0.8350 x N/A |
| Day's Range | 0.8000 - 0.8000 |
| 52 Week Range | 0.6450 - 2.3000 |
| Volume | |
| Avg. Volume | 279 |
| Market Cap | 97.228M |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5670 |
| Earnings Date | Mar 21, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.43 |
- GlobeNewswire
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fourth quarter and twelve months ended December 31, 2022 on March 21, 2023. The company will host a conference call and webcast on the same day at 9:00 a.m. ET to discuss these financial results and recent busines
- GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced that, effective on February 28, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to
- Zacks
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
